Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Health

>> RESPONDING Latest News

JUN 23, 2014 - Yahoo! News

A Must Read - Share

FDA staff question validity of benefit seen with AstraZeneca drug

(Reuters) - Staff reviewers at the U.S. Food and Drug Administration said AstraZeneca Plc's experimental ovarian cancer drug olaparib showed an 83 percent reduction in the risk of disease progression but questioned whether the result could be reproduced. The drug, olaparib, is designed as a maintenance treatment for certain women with relapsed ovarian cancer whose tumors are responding completely or in part to platinum-based chemotherapy. Patients in a clinical trial had a seven-month median improvement in progression-free survival. The staff report, published on the FDA's website ... Read More

Tags: FDA staff question validity of benefit seen with AstraZeneca drug,  Responding Latest News